# ulcerative colitis (UC) - deepseek-v4-flash

- Benchmark system: E2seq + Agent RAG
- Repeat: 2
- Task type: DISEASE-STATE
- Tissue / sample source: colonic mucosal tissue
- Comparison or endpoint: ulcerative colitis versus healthy control
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: 478acec7ab00f0e9bda085b6ecab7aa16a2bc8aa5cde3f2ba8fb71b2af94f79a
- Response HTTP status: 200
- Prompt tokens: 32248
- Completion tokens: 11239
- Reasoning tokens: 0
- Total tokens: 43487
- API requests reported: 2
- Elapsed seconds: 80.228
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1095.213
- Question handoff seconds: 1109.559
- Final benchmark system: E2seq; file rank 1/5; original repeat 2; model vendor: DeepSeek

---
# Multidimensional Interpretation of Ulcerative Colitis Transcriptomic Data (Colonic Mucosa, UC vs Healthy Control)

## 1. Overall Biological Interpretation

The transcriptomic profile of UC colonic mucosa relative to healthy controls is dominated by a coordinated **innate immune and inflammatory response** coupled with **loss of differentiated epithelial functions**. The most striking features are:

- **Upregulation of antimicrobial/innate defense genes** (SLC6A14, DUOX2/DUOXA2, LCN2, PI3, S100A8, CHI3L1, REG4, PLA2G2A) and **neutrophil/chemokine-recruiting signals** (CXCL1/2/3, VNN1).
- **Downregulation of mature colonocyte identity markers** — aquaporins (AQP7, AQP8), solute carriers (SLC16A1, SLC51A, SLC23A1/3), transporters (ABCG2, ABCB11), and metabolic enzymes (HMGCS2, G6PC, CYP2B6, GBA3).
- **Upregulation of tissue remodeling and matrix genes** (MMP3, TNC, TGM2, TIMP1, SERPINB5, PDPN, PRRX1, CDH3), suggesting active epithelial–mesenchymal transition and extracellular matrix (ECM) remodeling.
- **Downregulation of lipid/bile metabolism genes** (HMGCS2, SLC51A, ABCG2, ABCB11, CYP2B6, HSD3B2), indicating metabolic reprogramming of the inflamed epithelium.
- **Upregulation of adaptive immune regulators** (CTLA4, IL1RN, SOCS3, IRAK3, DAPP1), consistent with both inflammatory activation and counter-regulatory/negative-feedback responses.

The overall picture is one of **acute-on-chronic mucosal inflammation with epithelial dedifferentiation** — the inflamed UC mucosa shifts from a differentiated absorptive/secretory epithelium toward a reactive, proliferative, innate-immune-activated state.

---

## 2. Core Biological Programs

### Program 1: Innate Antimicrobial and Reactive Oxygen Defense
- **Direction:** Upregulated
- **Supporting genes:** DUOX2 (log2FC=4.67), DUOXA2 (2.89), SLC6A14 (4.85), LCN2 (2.67), PI3 (2.21), S100A8 (3.80), S100P (1.77), CHI3L1 (4.59), REG4 (2.05), PLA2G2A (1.53)
- **Pathway:** Reactome "Detoxification of Reactive Oxygen Species"; GO "antimicrobial humoral response"; KEGG "IL-17 signaling pathway" (CXCL1/2/3, S100A8)
- **Rationale:** DUOX2/DUOXA2 encode the dual-oxidase system that generates H₂O₂ for luminal antimicrobial defense. SLC6A14 is a neutral/basic amino acid transporter that is a well-established NF-κB target and is among the most strongly induced genes in IBD. LCN2 (lipocalin-2) is a siderophore-binding innate immune protein; S100A8 (calprotectin subunit) is a canonical neutrophil/monocyte marker. CHI3L1 and REG4 are epithelial restitution/antimicrobial proteins. The coordinated upregulation of these genes indicates activation of the intestinal epithelial antimicrobial program.
- **Evidence strength:** Strong. Multiple independent genes with extremely low FDR (all < 1e-10), coherent functional annotation, and well-established IBD literature support. **Limitation:** These genes are not UC-specific; similar patterns occur in Crohn's disease and infectious colitis. No independent cohort statistic was supplied.

### Program 2: Neutrophil Chemokine Recruitment and Inflammatory Amplification
- **Direction:** Upregulated
- **Supporting genes:** CXCL1 (3.46), CXCL2 (2.80), CXCL3 (2.33), VNN1 (3.20), MMP3 (4.64), IL1RN (2.88), SOCS3 (2.79), IRAK3 (1.78)
- **Pathway:** KEGG "IL-17 signaling pathway" (CXCL1, CXCL2, CXCL3); GO "chemokine activity"; Reactome "Chemokine receptors bind chemokines"
- **Rationale:** CXCL1/2/3 are ELR⁺ CXC chemokines that recruit neutrophils via CXCR2 (STRING evidence: CXCL1, CXCL2, CXCL3 all linked to CXCR2). VNN1 (vanin-1) is a pantetheinase involved in inflammatory responses. MMP3 is a matrix metalloproteinase induced by IL-17 and TNF. IL1RN (IL-1 receptor antagonist) and SOCS3 (suppressor of cytokine signaling) represent negative-feedback regulators that are co-induced with pro-inflammatory signals.
- **Evidence strength:** Strong for the inflammatory program itself. **Limitation:** The co-upregulation of IL1RN/SOCS3/IRAK3 indicates that the dataset captures both pro- and anti-inflammatory arms; the net functional consequence cannot be inferred from expression alone.

### Program 3: Loss of Differentiated Epithelial Transport and Metabolic Function
- **Direction:** Downregulated
- **Supporting genes:** AQP8 (log2FC=-4.42), AQP7 (-2.32), SLC16A1 (-2.38), SLC51A (-3.71), SLC23A1 (-2.40), SLC23A3 (-1.93), ABCG2 (-2.92), ABCB11 (-1.15), SLC19A3 (-1.34), SLC25A34 (-1.93)
- **Pathway:** GO "Water transport" (GO:0006833), "Fluid transport" (GO:0042044), "Carboxylic acid transport" (GO:0046942); KEGG "Bile secretion"
- **Rationale:** AQP7 and AQP8 are water channels expressed in normal colonocytes; their marked downregulation (AQP8 is the second-largest downregulation in the dataset) indicates loss of differentiated absorptive epithelium. SLC51A (OSTα) is a bile acid transporter; ABCG2 and ABCB11 are efflux transporters. SLC16A1 (MCT1) is a short-chain fatty acid transporter. The coordinated loss of these transporters is consistent with **epithelial dedifferentiation** rather than a targeted single-pathway defect.
- **Evidence strength:** Strong at the level of coordinated expression change. **Limitation:** This pattern could reflect either (a) true downregulation within epithelial cells or (b) **loss of epithelial cell fraction** due to immune cell infiltration and ulceration — a composition effect that cannot be distinguished from bulk tissue transcriptomics.

### Program 4: Epithelial–Mesenchymal Transition and ECM Remodeling
- **Direction:** Upregulated
- **Supporting genes:** MMP3 (4.64), TNC (2.58), TGM2 (1.91), TIMP1 (1.97), SERPINB5 (3.29), PDPN (2.54), PRRX1 (2.91), CDH3 (2.29), FILIP1L (1.86)
- **Pathway:** GO "extracellular matrix organization"; Reactome "Extracellular matrix organization"; KEGG "Rheumatoid arthritis" (MMP3, CXCL1/2/3 — reflecting shared inflammatory-ECM programs)
- **Rationale:** MMP3 is a potent ECM-degrading enzyme; TNC (tenascin-C) and TGM2 (tissue transglutaminase) are ECM-remodeling proteins upregulated in IBD. PDPN (podoplanin) and PRRX1 are markers of mesenchymal/EMT states. TIMP1 is the MMP inhibitor, suggesting a coordinated matrix turnover program rather than unopposed degradation.
- **Evidence strength:** Moderate-to-strong. Multiple genes with coherent function. **Limitation:** PRRX1 and PDPN upregulation could reflect **stromal cell expansion** (myofibroblasts, lymphatic endothelium) rather than epithelial EMT per se; single-cell resolution is needed to distinguish cellular origin.

### Program 5: Metabolic Reprogramming — Loss of Lipid/Ketone and Xenobiotic Metabolism
- **Direction:** Downregulated
- **Supporting genes:** HMGCS2 (-3.45), G6PC (-1.52), CYP2B6 (-2.78), CYP2B7P (-2.72), UGT2A3 (-2.68), HSD3B2 (-2.77), GBA3 (-3.00), ACSF2 (-1.93), ETNK1 (-1.58), TAT (-1.19)
- **Pathway:** KEGG "Bile secretion"; GO "lipid metabolic process"; Reactome "Metabolism"
- **Rationale:** HMGCS2 (mitochondrial HMG-CoA synthase) is a key enzyme in ketogenesis and a marker of differentiated colonocytes. G6PC (glucose-6-phosphatase) is a gluconeogenic enzyme. CYP2B6 and UGT2A3 are xenobiotic-metabolizing enzymes. GBA3 is a glucosidase. The coordinated downregulation indicates suppression of the differentiated epithelial metabolic program in favor of a proliferative/inflammatory metabolic state.
- **Evidence strength:** Moderate. The genes are coherent but span multiple metabolic pathways; the "program" is best described as **loss of epithelial metabolic specialization** rather than a single pathway. **Limitation:** Some of these genes (e.g., CYP2B6) show tissue-specific expression that may be diluted or lost in inflamed tissue; composition effects again apply.

---

## 3. Key Genes and Interaction Modules

### 1. DUOX2 / DUOXA2 module
- **Direction:** Upregulated (DUOX2 log2FC=4.67; DUOXA2 log2FC=2.89)
- **Role:** Innate antimicrobial defense via H₂O₂ production.
- **Relationship:** DUOXA2 is the maturation factor for DUOX2 — a **direct physical interaction** (required for functional expression).
- **Evidence:** Direct input statistics; Reactome "Detoxification of Reactive Oxygen Species" pathway membership; extensive IBD literature.

### 2. CXCL1 / CXCL2 / CXCL3 chemokine module
- **Direction:** All upregulated (log2FC=3.46, 2.80, 2.33)
- **Role:** Neutrophil recruitment via CXCR2.
- **Relationship:** All three chemokines bind the same receptor CXCR2 — **pathway co-membership** (ligand–receptor relationship, not direct physical interaction between the chemokines themselves). STRING evidence supports CXCR2 as a shared interaction partner.
- **Evidence:** Direct input; KEGG IL-17 signaling pathway; STRING network.

### 3. SLC6A14
- **Direction:** Upregulated (log2FC=4.85, the largest positive effect in the dataset)
- **Role:** Amino acid transporter; NF-κB target; implicated in IBD pathogenesis.
- **Relationship:** No direct interaction partners in the current network evidence; its role is as a downstream effector of inflammatory signaling.
- **Evidence:** Direct input; strong IBD literature association. **Note:** A single gene with a large effect size does not by itself establish a program — it is included here because it is the top hit and has independent literature support.

### 4. MMP3 / TIMP1 module
- **Direction:** Both upregulated (MMP3 log2FC=4.64; TIMP1 log2FC=1.97)
- **Role:** ECM degradation and its inhibition — a balanced matrix turnover program.
- **Relationship:** TIMP1 is a direct **protein inhibitor** of MMP3 (direct physical interaction, well-established biochemistry).
- **Evidence:** Direct input; STRING/IntAct records; extensive literature.

### 5. AQP7 / AQP8 module
- **Direction:** Both downregulated (AQP8 log2FC=-4.42; AQP7 log2FC=-2.32)
- **Role:** Water transport; markers of differentiated colonocytes.
- **Relationship:** Both are members of the aquaporin family and share the "Passive transport by Aquaporins" Reactome pathway — **pathway co-membership**. STRING lists AQP11 and AQP12A as interaction partners, suggesting family-level co-regulation.
- **Evidence:** Direct input; Reactome; MyGene KEGG "Bile secretion" annotation for AQP8. **Limitation:** The downregulation may reflect loss of epithelial cells rather than active transcriptional repression.

### 6. S100A8 (calprotectin subunit)
- **Direction:** Upregulated (log2FC=3.80)
- **Role:** Neutrophil/monocyte marker; alarmin; forms the S100A8/S100A9 heterodimer (calprotectin) used clinically as a fecal biomarker.
- **Relationship:** S100A8 forms a heterodimer with S100A9 (direct physical interaction, well-established); S100A9 was not among the top selected genes but the heterodimer biology is relevant. STRING shows S100A8–CDH1 interaction (putative, likely indirect via cell-adhesion context).
- **Evidence:** Direct input; strong clinical biomarker literature (fecal calprotectin).

### 7. SOCS3 / IRAK3 / IL1RN — negative-feedback regulators
- **Direction:** All upregulated (SOCS3 log2FC=2.79; IRAK3 log2FC=1.78; IL1RN log2FC=2.88)
- **Role:** Suppressors of cytokine signaling (SOCS3 inhibits JAK/STAT; IRAK3 inhibits TLR/IL-1R signaling; IL1RN blocks IL-1 receptor).
- **Relationship:** These are **functionally related but not direct physical interactors**; they represent parallel negative-feedback loops within the inflammatory program (**pathway co-membership** in inflammatory signaling).
- **Evidence:** Direct input; TRRUST regulatory records (31/100 genes covered); literature.

### 8. CTLA4
- **Direction:** Upregulated (log2FC=2.62)
- **Role:** T-cell inhibitory checkpoint; adaptive immune regulation.
- **Relationship:** No direct interaction partners in the current network evidence; its upregulation suggests infiltration/activation of regulatory T cells or exhausted effector T cells.
- **Evidence:** Direct input; extensive immunology literature. **Limitation:** Bulk tissue cannot distinguish which T-cell subset expresses CTLA4.

### 9. PRRX1 / PDPN / TNC — mesenchymal markers
- **Direction:** All upregulated (PRRX1 log2FC=2.91; PDPN log2FC=2.54; TNC log2FC=2.58)
- **Role:** Markers of mesenchymal/EMT and stromal remodeling.
- **Relationship:** STRING evidence links TNC with ITGB1 and TGM2 (network co-membership; TNC–ITGB1 is a known ligand–receptor interaction). PRRX1 is a transcription factor that can drive EMT — **regulatory interaction** potential (PRRX1 regulates downstream EMT genes), but this is not demonstrated in the current dataset.
- **Evidence:** Direct input; STRING; literature.

### 10. HMGCS2
- **Direction:** Downregulated (log2FC=-3.45)
- **Role:** Ketogenesis; marker of differentiated colonocyte metabolism.
- **Relationship:** No direct interaction partners in the current network evidence. Its downregulation is best interpreted as part of the epithelial dedifferentiation program.
- **Evidence:** Direct input; literature on colonocyte metabolism.

---

## 4. Validation Priorities

### Priority 1: Distinguish epithelial-intrinsic changes from immune-cell infiltration (Confounding / composition check)
- **Why:** The downregulation of AQP8, SLC51A, ABCG2, HMGCS2 and the upregulation of S100A8, CXCL1/2/3, CTLA4 could reflect **changes in cell-type proportions** (loss of colonocytes, gain of neutrophils/T cells) rather than transcriptional changes within a fixed cell population.
- **Current dataset evidence:** Bulk tissue transcriptomics; the pattern is consistent with both hypotheses.
- **External evidence:** Single-cell RNA-seq studies of UC mucosa have shown both epithelial-intrinsic changes and immune infiltration; the composition effect is well documented.
- **Next step:** Single-cell or single-nucleus RNA-seq on matched UC vs control mucosa; or computational deconvolution (e.g., CIBERSORTx, MuSiC) of the current bulk data.
- **Conclusion status:** The biological programs are **supported hypotheses**; the cellular origin of the changes is **insufficient evidence** from the current data alone.

### Priority 2: Validate DUOX2/DUOXA2–SLC6A14 antimicrobial axis as a mechanistic driver (Mechanistic hypothesis)
- **Why:** These are the largest positive effects (log2FC=4.67 and 4.85) and are biologically coherent (antimicrobial defense).
- **Current dataset evidence:** Strong coordinated upregulation with extremely low FDR.
- **External evidence:** DUOX2 is upregulated in IBD and is a known NF-κB target; SLC6A14 is a well-replicated IBD gene. **Conflict:** The functional role (protective antimicrobial vs. tissue-damaging ROS) remains debated.
- **Next step:** In vitro stimulation of intestinal epithelial organoids with inflammatory cytokines (TNF/IL-17/IFNγ) and measurement of DUOX2/SLC6A14 induction and ROS production; or genetic perturbation (CRISPR) in organoids.
- **Conclusion status:** **Supported hypothesis** for association; the causal/protective role is **exploratory**.

### Priority 3: Test CXCL1/2/3–CXCR2 axis as a therapeutic target for neutrophil recruitment (Therapeutic target)
- **Why:** Neutrophil infiltration is a hallmark of active UC; CXCR2 antagonism is an attractive target.
- **Current dataset evidence:** Coordinated upregulation of all three CXCR2 ligands.
- **External evidence:** CXCR2 antagonists exist and have been tested in other inflammatory conditions; the IL-17–CXCL axis is implicated in IBD. **Caveat:** Drug existence does not imply efficacy in UC; the pathway is also important for host defense.
- **Next step:** Preclinical testing of CXCR2 antagonists in mouse colitis models (e.g., DSS-induced colitis) with measurement of neutrophil infiltration and disease severity.
- **Conclusion status:** **Exploratory hypothesis** — the target is plausible and supported by expression data, but efficacy is unproven.

### Priority 4: Validate AQP8 and HMGCS2 as markers of epithelial restitution (Biomarker)
- **Why:** If confirmed, their recovery could track mucosal healing.
- **Current dataset evidence:** Marked downregulation (AQP8 log2FC=-4.42; HMGCS2 log2FC=-3.45).
- **External evidence:** AQP8 downregulation in UC has been reported; HMGCS2 is a colonocyte differentiation marker. **Limitation:** Both are likely to be confounded by epithelial loss (composition effect).
- **Next step:** Longitudinal sampling of UC patients before/after therapy; correlate AQP8/HMGCS2 expression with endoscopic healing; or measure protein levels in biopsy tissue by immunohistochemistry.
- **Conclusion status:** **Exploratory hypothesis** — promising but requires composition adjustment.

### Priority 5: Investigate the SOCS3/IRAK3/IL1RN negative-feedback module as a determinant of treatment response (Interaction / network hypothesis)
- **Why:** The co-upregulation of pro-inflammatory (CXCL, MMP3) and anti-inflammatory (SOCS3, IRAK3, IL1RN) genes suggests a dynamic balance that may predict response to anti-TNF or anti-IL-17 therapy.
- **Current dataset evidence:** All three negative regulators are upregulated with FDR < 1e-10.
- **External evidence:** IRAK3 has been linked to immune regulation in other inflammatory contexts (see PMID 40918148); SOCS3 is a well-known JAK/STAT inhibitor. **Conflict:** The literature record for IRAK3 is from T2DM/MAFLD, not UC — the relevance to UC is **insufficient evidence**.
- **Next step:** Correlate expression of these regulators with clinical response in a treatment cohort; or test in a mouse colitis model with SOCS3/IRAK3 modulation.
- **Conclusion status:** **Exploratory hypothesis**.

---

## 5. Evidence Grounding

| Claim | Direct input evidence | Pathway/ontology | Interaction/regulatory | Disease association | Literature | Independence assessment |
|---|---|---|---|---|---|---|
| Innate antimicrobial program (DUOX2, SLC6A14, LCN2, S100A8) | Strong (FDR < 1e-10 for all) | Reactome ROS detox; GO antimicrobial | DUOX2–DUOXA2 direct interaction | Well-established in IBD | Extensive (PMID 41029776, 38059894) | **Partially independent** — the input statistics are independent; the pathway and literature records draw on overlapping prior knowledge of the same genes |
| Neutrophil chemokine program (CXCL1/2/3) | Strong | KEGG IL-17 signaling | CXCR2 receptor co-membership (STRING) | Well-established in IBD | Extensive | **Partially independent** — chemokine biology is well characterized, but the specific UC relevance in this cohort is new |
| Epithelial dedifferentiation (AQP8, SLC51A, ABCG2, HMGCS2 down) | Strong | GO water/carboxylic acid transport; KEGG bile secretion | None specific | AQP8 down in UC reported | Some (PMID 25171508 for BRINP3; others) | **Weakly independent** — the pattern is coherent but the composition confound is unresolved |
| ECM remodeling (MMP3, TNC, TGM2, TIMP1) | Strong | GO ECM organization | TIMP1–MMP3 direct inhibition (well-established) | MMP3 in IBD well-known | Extensive | **Partially independent** |
| Adaptive immune checkpoint (CTLA4) | Strong (single gene) | None specific in current records | None in current records | CTLA4 in IBD T cells | Extensive | **Insufficient evidence** for a program based on a single gene; needs additional T-cell genes for support |

**Conflicts:**
- The **pro-inflammatory** (CXCL, MMP3) and **anti-inflammatory** (IL1RN, SOCS3, IRAK3) genes are both upregulated — this is not contradictory per se (negative feedback is expected), but the net effect cannot be inferred from expression alone.
- The DUOX2/ROS program is protective (antimicrobial) but potentially tissue-damaging — the direction of net effect is unresolved.
- The downregulation of metabolic/transport genes could be a **cause** of epithelial dysfunction or a **consequence** of inflammation — the current cross-sectional design cannot distinguish these.

**External statistical validation:** Not performed. No independent-cohort statistics were supplied. The pathway, interaction, and literature records are contextual and do not constitute replication.

---

## 6. Limitations and Alternative Explanations

### 1. Tissue/Cell-Composition Effects (most important)
The inflamed UC mucosa contains more neutrophils, macrophages, T cells, and myofibroblasts and fewer differentiated colonocytes than healthy mucosa. The observed downregulation of AQP8, SLC51A, ABCG2, HMGCS2, and the upregulation of S100A8, CTLA4, PDPN, PRRX1 could be **largely explained by cell-type proportion shifts** rather than cell-intrinsic transcriptional changes.
- **Investigation:** Single-cell RNA-seq; computational deconvolution; or laser-capture microdissection of epithelial vs. lamina propria compartments.

### 2. Disease Severity and Extent
UC is heterogeneous — the transcriptomic signature likely reflects the **severity and extent** of the sampled lesions. If most samples came from active, severely inflamed regions, the inflammatory and dedifferentiation programs would be over-represented relative to quiescent UC.
- **Investigation:** Stratify by Mayo endoscopic subscore, disease extent (proctitis/left-sided/pancolitis), and histologic activity.

### 3. Treatment Exposure
Many UC patients receive 5-ASA, corticosteroids, immunomodulators, or biologics. These treatments directly modulate the inflammatory programs measured here (e.g., steroids suppress CXCL chemokines; anti-TNF affects MMP3). If treatment data are not available, the signature may reflect **treatment response status** rather than disease biology per se.
- **Investigation:** Collect medication history; stratify by treatment class; or restrict to treatment-naive patients.

### 4. Batch/Platform Effects and Probe Ambiguity
The dataset contains 43 duplicated genes/probes and several ambiguous rows (e.g., "CYP2B7P|CYP2B6", "NAT8B|NAT8", "LOC100290146|IGHV4-31|IGHM|IGHG1|IGH"). The immunoglobulin locus row is particularly problematic — it may reflect **contamination or B-cell infiltration** rather than a specific gene change. Probe-level artifacts (e.g., PROBE_241592_PM_at, PROBE_227140_PM_at, PROBE_235105_PM_at) cannot be assigned to genes.
- **Investigation:** Confirm key findings by qRT-PCR or RNA-seq; exclude ambiguous probes from downstream analyses; check for batch effects using principal-component analysis.

### 5. Association-versus-Causation Ambiguity
All findings are cross-sectional associations. The upregulation of DUOX2/SLC6A14 could be a **cause** of inflammation (via ROS) or a **protective response** to it. The downregulation of AQP8 could drive diarrhea or merely reflect epithelial loss. No causal inference is possible from this design.
- **Investigation:** Longitudinal sampling; Mendelian randomization using cis-eQTLs; or functional perturbation in organoids/animal models.

---

## Summary

The current transcriptomic data provide strong statistical evidence (all 100 genes at FDR < 4e-10) for a coordinated UC mucosal signature comprising: (1) innate antimicrobial activation (DUOX2/DUOXA2, SLC6A14, S100A8, LCN2), (2) neutrophil chemokine recruitment (CXCL1/2/3), (3) loss of differentiated epithelial transport/metabolic function (AQP8, SLC51A, ABCG2, HMGCS2), (4) ECM remodeling (MMP3, TNC, TGM2), and (5) co-induced negative-feedback regulators (SOCS3, IRAK3, IL1RN). These programs are biologically coherent and consistent with published IBD literature. The major unresolved issues are the **cellular origin of the changes** (composition effects), the **treatment context** of the samples, and the **lack of independent-cohort validation** — none of which were supplied in the current data. The most defensible next steps are single-cell validation of the epithelial dedifferentiation and immune-infiltration programs, and functional testing of the DUOX2/SLC6A14 and CXCL–CXCR2 axes in relevant model systems.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=16, external claims checked=0, external mismatches=0, status=passed.

Answer model API: deepseek / deepseek-v4-flash.

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 94/100 selected items (records returned); cbioportal 87/100 selected items (records returned); chembl 40/100 selected items (partially returned; some queries failed); civic 7/100 selected items (records returned); clinicaltrials 51/100 selected items (records returned); clinvar 90/100 selected items (records returned); ensembl 55/100 selected items (partially returned; some queries failed); europepmc 936 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 91/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 85/100 selected items (records returned); humanbase 87/100 selected items (records returned); intact 85/100 selected items (records returned); mygene 93/100 selected items (records returned); omnipath 45/100 selected items (records returned); opentargets 92/100 selected items (records returned); pubmed 750 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 87/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 88/100 selected items (records returned)
Local databases: gutmgene 8/100 selected items (records returned); hmdb 46/100 selected items (records returned); string 85/100 selected items (records returned); trrust 31/100 selected items (records returned)
